BioNTech Falls Short In Jittery IPO Market

Investors also readjust to firm's unproven pipeline

After ADC Therapeutics postponed its launch last week, BioNTech braves the markets but finds them less receptive than hoped.

Cautioin — Investors wary of jumping into public offerings • Source: Shutterstock

German biotech company BioNTech AG has raised $150m in its NASDAQ initial public offering, a much lower figure than it had hoped to generate.

This was around $100m less than its target, and reflects wider turbulence on the public markets. High profile IPOs from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.